GIPC PDZ domain containing family member 3Genealiases: C19orf64 · DFNB15 · DFNB72 · DFNB95
Q-omics provides the consensus-scored GIPC3 profile across patient tissues and cancer cell-line models. GIPC3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GIPC3 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, GIPC3 RNA expression shows 18,030 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, HNSC, and TGCT as cancer lineages where GIPC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GIPC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GIPC3 survival associations across molecular data types. GIPC3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GIPC3 RNA expression–survival associations across cancer types. High GIPC3 expression shows unfavorable associations in KIRP, ACC, MESO, LGG and STAD, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GIPC3 RNA expression.
This table summarizes GIPC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GIPC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GIPC3 shows lower tumor expression in KICH, KIRP, LUSC and LUAD and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher GIPC3 RNA expression in tumor versus normal tissue (log2 FC = +0.957, t-test p < 0.001).
This table shows molecular features associated with GIPC3 in patient tissues and cancer cell lines. In patient samples, GIPC3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GIPC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
